The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China

摘要

The long-term prognosis of patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving different treatments is deserved to be analyzed in modern era of CTEPH treatment. From 2013 to 2019, a total of 364 patients diagnosed with CTEPH were retrospectively included, 14 patients were lost during follow-up. Among 350 patients included in the final analysis: 123 underwent pulmonary endarterectomy (PEA), 121 received balloon pulmonary angioplasty (BPA), and 106 treated with targeted drug alone. The median period of follow-up was 51.2 months, the estimated survival at 1-, 3-, 5- and 7-year was 97.1, 93.3, 86.9, and 82.0 for the whole cohort; 100, 99.20, 96.5 and 92.5 in PEA group; 98.4, 97.4, 95.3 and 89.3 in BPA group;92.5, 81.9, 70.1 and 66.8 in patients who received targeted drug alone. In comparing with targeted treatment along, results of multivariate Cox analysis after adjusting the confounders showed that receiving PEA decreased the risk of death by 83 (HR hazard ratio 0.17, 95 CI Confidence interval 0.07-0.44) and receiving BPA decreased the risk of death by 89 (HR 0.11, 95 CI 0.04-0.29). In conclusion, the estimated survival of CTEPH patients at 1-, 3-, 5- and 7-year was 97.1, 93.3, 86.9, and 82.0 respectively. The intervention of revascularization, including PEA and BPA, were preferred than treating with targeted drug alone in the view of long-term prognosis of CTEPH.